Nuvectis Pharma (NVCT) VP awarded 61,200 restricted shares of stock

Rhea-AI Filing Summary

Nuvectis Pharma vice president receives new equity grant. Nuvectis Pharma, Inc. reported that its Vice President of Finance, Michael J. Carson, was awarded 61,200 shares of restricted common stock on January 6, 2026. The grant was priced at $0 per share, reflecting a stock award rather than an open-market purchase.

The 61,200 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, and are conditioned on Mr. Carson’s continued service. After this grant, Mr. Carson beneficially owns a total of 200,118 shares of Nuvectis Pharma common stock, including restricted shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Carson Michael J.

Role Vice President, Finance

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	61,200	$0.00	--

Holdings After Transaction: Common Stock — 200,118 shares (Direct)

Footnotes (1)

1. The 61,200 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Carson's continued service on such dates. Includes shares of restricted common stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carson Michael J.

(Last) (First) (Middle)

C/O NUVECTIS PHARMA, INC.

1 BRIDGE PLAZA, SUITE 275

(Street)

FORT LEE NJ 07024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvectis Pharma, Inc. [ NVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Vice President, Finance

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		A		61,200(1)	A	$0	200,118(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The 61,200 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Carson's continued service on such dates.

2. Includes shares of restricted common stock.

	/s/ Michael Carson	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NVCT disclose in this Form 4?

Nuvectis Pharma, Inc. disclosed that its Vice President of Finance, Michael J. Carson, received an award of 61,200 shares of restricted common stock on January 6, 2026.

How many Nuvectis Pharma (NVCT) shares did the executive receive and at what price?

Michael J. Carson was granted 61,200 shares of Nuvectis Pharma common stock at a reported price of $0 per share, indicating an equity award rather than a market purchase.

What is the vesting schedule for the 61,200 restricted NVCT shares?

The 61,200 restricted shares will vest in equal annual installments over three years, starting on the first anniversary of the grant date, subject to Mr. Carson’s continued service.

What is Michael J. Carson’s role at Nuvectis Pharma?

Michael J. Carson is an officer of Nuvectis Pharma, Inc., serving as Vice President, Finance.

How many Nuvectis Pharma shares does the executive own after this transaction?

Following the award, Michael J. Carson beneficially owns 200,118 shares of Nuvectis Pharma common stock, which includes shares of restricted common stock.

Is the ownership reported in this NVCT Form 4 direct or indirect?

The Form 4 reports Mr. Carson’s ownership as direct (D), with the total of 200,118 shares held directly in his name.